Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Innocoll, a biopharmaceutical company, has announced that its wholly-owned subsidiary, Innocoll Pharmaceuticals, has filed a US 510k application for its CollaRx lidocaine sponge for the management of painful wounds.
Subscribe to our email newsletter
According to the company, the CollaRx lidocaine sponge is a lyophilized collagen sponge containing purified type-I collagen protein and lidocaine, a locally acting anesthetic.
The product is intended to be used for the management of painful wounds including: diabetic ulcers, venous ulcers, pressure ulcers, ulcers caused by mixed vascular etiologies, full-thickness and partial thickness wounds, abrasions, traumatic wounds, first and second degree burns and dehisced surgical wounds.
Michael Myers, president and CEO of Innocoll, said: “I am very pleased about the progress that we have made with the CollaRx lidocaine sponge. This marks our third medical device filing in the US, and demonstrates the versatility of our collagen based drug delivery technology.”